Fri, Sep 19, 2014, 10:41 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Corrections Corporation of America Message Board

sam_0534 217 posts  |  Last Activity: 2 hours 12 minutes ago Member since: Feb 8, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Teva currently carries a Zacks Rank #2 (Buy). Some better-ranked companies in the health care sector include Mallinckrodt plc (MNK), Allergan (AGN) and AstraZeneca (AZN). All three are Zacks Rank #1 (Strong Buy) stocks.

    Sentiment: Strong Buy

  • Thank you for voting. Your instructions have been received and recorded for:

    MALLINCKRODT PLC
    Meeting to be held on Thursday, August 14, 2014
    For Shareholders of record as of Wednesday, July 9, 2014
    CUSIP: G5785G107

    Sentiment: Strong Buy

  • FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
    OMB Number: 3235-0287
    Expires: December 31, 2014
    Estimated average burden
    hours per response: 0.5



    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person *PAULSON & CO INC

    --------------------------------------------------------------------------------
    (Last) (First) (Middle)
    1251 AVENUE OF THE AMERICAS


    --------------------------------------------------------------------------------
    (Street)NEW YORK NY 10020

    --------------------------------------------------------------------------------
    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Mallinckrodt plc [ MNK ] 5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable) Director X 10% Owner
    Officer (give title below) Other (specify below)


    3. Date of Earliest Transaction (Month/Day/Year)
    08/11/2014
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person
    Form filed by More than One Reporting Person

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares, $0.20 par value (1) (2) 08/11/2014 P 107,900 A $ 69.4986 7,807,900 I (1) (2) By Managed Funds and Accounts
    Ordinary Shares, $0.20 par value (1) (2) 08/11/2014 P 100,000 A $ 69.91 7,907,900 I (1) (2) By Managed Funds and Accounts
    Ordinary Shares, $0.20 par value (1) (2) 08/12/2014 P 120,000 A $ 67.855 8,027,900 I (1) (2) By Managed Funds and Accounts
    Ordinary Shares, $0.20 par value (1) (2) 08/12/2014 P 140,000 A $ 68.2034 8,167,900 I (1) (2) By Managed Funds and Accounts
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Paulson & Co. Inc. ("Paulson") is an investment advisor registered under the Investment Advisors Act of 1940. Paulson is the investment manager of Paulson Partners Enhanced LP, Paulson Enhanced Ltd, Paulson International Ltd, Paulson Partners LP and Paulson Partners Premium LP (collectively, the "Funds") and certain separately managed accounts (the "Separately Managed Accounts"). John Paulson is the controlling person of Paulson. All securities reported on this Form 4 are owned by the Funds or held in the Separately Managed Accounts.
    2. Each of Paulson and John Paulson may be deemed to indirectly beneficially own the securities directly owned by the Funds or held in the Separately Managed Accounts. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Act"), the filing of this Form 4 shall not be deemed an admission by any person reporting on this Form 4 that such person, for purposes of Section 16 of the Act or otherwise, is the beneficial owner of any equity securities covered by this Form.
    /s/ Stuart L. Merzer, General Counsel & Chief Compliance Officer 08/13/2014
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

    Sentiment: Strong Buy

  • stocastics very oversold...

    Sentiment: Strong Buy

  • FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
    OMB Number: 3235-0287
    Expires: December 31, 2014
    Estimated average burden
    hours per response: 0.5



    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person *PAULSON & CO INC

    --------------------------------------------------------------------------------
    (Last) (First) (Middle)
    1251 AVENUE OF THE AMERICAS


    --------------------------------------------------------------------------------
    (Street)NEW YORK NY 10020

    --------------------------------------------------------------------------------
    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Mallinckrodt plc [ MNK ] 5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable) Director X 10% Owner
    Officer (give title below) Other (specify below)


    3. Date of Earliest Transaction (Month/Day/Year)
    08/07/2014
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person
    Form filed by More than One Reporting Person

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares, $0.20 par value (1) (2) 08/07/2014 P 200,000 A $ 69.6911 7,199,800 I (1) (2) By Managed Funds and Accounts
    Ordinary Shares, $0.20 par value (1) (2) 08/07/2014 P 500,200 A $ 70.3389 7,700,000 I (1) (2) By Managed Funds and Accounts
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Notional Principal Amount Derivative Agreement (1) (2) $ 69.9223 08/07/2014 J /K (3) 1 (3) 07/17/2015 Ordinary Shares, $0.20 par value 16,500 (3) 1 I (3) By Managed Funds and Accounts
    Explanation of Responses:
    1. Paulson & Co. Inc. ("Paulson") is an investment advisor registered under the Investment Advisors Act of 1940. Paulson is the investment manager of Paulson Partners Enhanced LP, Paulson Enhanced Ltd, Paulson International Ltd, Paulson Partners LP and Paulson Partners Premium LP (collectively, the "Funds") and certain separately managed accounts (the "Separately Managed Accounts"). John Paulson is the controlling person of Paulson. All securities reported on this Form 4 are owned by the Funds or held in the Separately Managed Accounts.
    2. Each of Paulson and John Paulson may be deemed to indirectly beneficially own the securities directly owned by the Funds or held in the Separately Managed Accounts. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Act"), the filing of this Form 4 shall not be deemed an admission by any person reporting on this Form 4 that such person, for purposes of Section 16 of the Act or otherwise, is the beneficial owner of any equity securities covered by this Form.
    3. Notional principal amount derivative agreement (the "Derivative Agreement") in the form of a cash settled swap entered into by a Separately Managed Account representing a share equivalent of an aggregate of 16,500 Ordinary Shares. The Derivative Agreement provides the Separately Managed Account with economic results that are comparable to the economic results of ownership of Ordinary Shares payable on each settlement date applicable to the expiration or earlier termination of such Derivative Agreement, but does not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the Ordinary Shares that are the subject of the Derivative Agreement (such shares, the "Subject Shares"). Each of Paulson, the Funds, the Separately Managed Accounts and John Paulson disclaims beneficial ownership in the Subject Shares. The counterparty to the Derivative Agreement is an unaffiliated third party financial institution.
    /s/ Stuart L. Merzer, General Counsel & Chief Compliance Officer 08/12/2014
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

  • If MNK breaks above the recent new high of 87.15... it looks like a flag pattern giving a 15 point more..willneed good volume on the break out.. will see.. never know..stocastics and RS is high... overbought..but can stay that way.. made a few mistakes selling on overbought..

    Sentiment: Buy

  • sam_0534 by sam_0534 Jul 18, 2014 9:43 AM Flag

    NEW YORK (TheStreet) -- JMP Securities increased its price target on The Blackstone Group (BX_) to $44, increased its estimates and set a "buy" rating, as the company is seeing higher asset growth.

    Sentiment: Strong Buy

  • so they have a valid platform and would expect others to follow...just need to be patient...

    Sentiment: Strong Buy

  • will be a base for a big move IMHO...

    Sentiment: Strong Buy

  • sam_0534 sam_0534 Jul 2, 2014 9:58 AM Flag

    you are wasting others time here with your posts...I will have to put you on IGNORE and others should too if you keep up your foolish posts... ciao

    Sentiment: Buy

  • sam_0534 by sam_0534 Aug 14, 2014 4:44 PM Flag

    Questcor Pharma: Deal Expected to Add Significantly to Adjusted EPS in Fiscal 2015

    Sentiment: Strong Buy

  • FOR IMMEDIATE RELEASE

    Intellipharmaceutics Augments its Rexista™ Oxycodone Development Program with Novel Overdose Deterrence Technology

    Toronto, Ontario, August 28th, 2014 – Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced an enhancement of its Rexista™ abuse-deterrence technologies with a significant improvement designed to prevent overdose when more pills than prescribed are swallowed intact. Intellipharmaceutics’ new platform technology is branded PODRAS™ (Paradoxical OverDose Resistance Activating System).

    The PODRAS™ platform technology is covered by patents pending with the U.S. Patent and Trademark office.

    “We believe this significant advance in our abuse deterrence technology has the potential to positively differentiate Rexista™ from other abuse-deterrent technologies of which we are aware, and represents an important step towards helping patients manage their pain safely,” said Dr. Isa Odidi, Chief Executive Officer of Intellipharmaceutics. “In addition to its use with oxycodone, the new technology is potentially applicable to a wide range of drug products that are intentionally or inadvertently abused and cause harm by overdose to those who ingest them.”

    Intellipharmaceutics’ most advanced application of the PODRAS™ platform to date is to its Rexista™ product candidate (oxycodone hydrochloride extended-release tablet), which is designed to deter abuse by both physical interference and overdose.

    Preclinical studies of Rexista™ suggest that, unlike other third-party abuse-deterrent oxycodone products, if more tablets than prescribed are deliberately or inadvertently swallowed, the amount of drug active released over 24 hours may be substantially less than expected, even possibly approaching zero. However, if the prescribed number of pills is swallowed, the drug release should be as expected.

    In January 2013, the United States Food and Drug Administration (“FDA”) published a paper titled, Guidance for Industry: Abuse-Deterrent Opioids — Evaluation and Labeling, which cited the need for more efficacious abuse deterrence-technology.

    In this draft Guidance, the FDA stated, “Opioid analgesics are often manipulated for purposes of abuse. Most abuse-deterrent technologies developed to date are designed to make product manipulation more difficult or to make abuse of the manipulated product less attractive or rewarding. However, these technologies have not yet proven successful at deterring the most common form of abuse – swallowing a number of intact pills or tablets to achieve a feeling of euphoria.”

    Dr. Ed Sellers, an internationally recognized clinical pharmacologist and Professor Emeritus, University of Toronto, and President of DL Global Partners commented "The risk of overdose due to taking more opiate analgesic than prescribed is a real one. The lack of delivery technologies to reduce that risk is an unmet public health need. The announced technology is promising. Confirmation of its clinical importance in human clinical studies would be a significant contribution to deterring abuse.”

    Intellipharmaceutics currently expects to begin a series of clinical trials in Canada and the United States in the coming months to further evaluate Rexista™ incorporating its PODRAS™ platform.

    There can be no assurance as to whether or when the FDA will approve any Intellipharmaceutics' Rexista™ oxycodone application.

    Sentiment: Strong Buy

  • sam_0534 sam_0534 Aug 20, 2014 4:04 PM Flag

    yes.. Mission Accomplished by your Bush AH.. 1 trillion spent and allthe dead and wounded...you are the loser for voting Republican..

  • sam_0534 sam_0534 Sep 18, 2014 2:32 PM Flag

    would think it would move off the older high.. sluggish here..traders are weary I guess...

  • Eircom Pulls Share Sale as Investors Favor Holding for Value
    By Joe Brennan Sep 19, 2014 11:28 AM PT 0 Comments Email Print
    Facebook
    Twitter
    Google+
    LinkedIn
    Save
    Eircom Group, the Irish phone carrier controlled by lenders led by Blackstone Group LP (BX), pulled plans to join the stock market for the third time in 15 years as shareholders concluded they would extract more value by not selling shares at this time.

    Eircom’s main shareholders “expressed their clear preference to continue participating in the upside” from investment in its telecommunications network in recent years, which has only recently begun to feed into its financial results, it said in a statement.

    Feedback from potential investors suggested a valuation, including debt, of between 2.8 billion euros ($3.6 billion) and 3.3 billion euros and that that 3 billion euros was achievable, said a person with knowledge of the matter, who asked not to be named because the matter is private.

    “The company declines to comment on the possible valuation range that was under consideration,” Dublin-based Eircom said in an e-mailed statement.

    Eircom came out of bankruptcy protection two years ago after creditors wrote off 40 percent of its more than 4 billion euros ($5.1 billion) in gross debt, which was accumulated during a series of ownership changes. The company was planning to raise as much as 1 billion euros through a sale sale to further reduce its debt position, three people familiar with the matter said on Sept. 12.

    O’Reilly Takeover

    The former state-owned carrier held its initial public offering in 1999. Two years later, the company was taken over by a group led by Irish businessman Anthony O’Reilly. Eircom returned to the stock market in 2004, before it was acquired in 2006 in another leveraged buyout.

    Eircom lists the group led by Blackstone’s credit units as its largest shareholder, with a 24.4 percent stake, followed by Anchorage Capital Group entities, with 8 percent, and Credit Suisse Group AG with 6.3 percent, according to an Aug. 28 bondholder filing. The current senior lenders are Eircom’s seventh set of owners.

    Eircom hired Rothschild, Goldman Sachs Group Inc. and Morgan Stanley earlier this year to advise on options for the business.

    Sentiment: Strong Buy

  • Microsoft, Blackstone are Underpriced Giants Says Oceanic Manager
    Up Next:

    Source ETFs Unveils Euro Stoxx 50 Fund as Initial U.S. Offering

    02:05PM 09/16/14

    0
    inShare

    Gregg Greenberg Follow
    9/16/14 2:10 PM EDT
    Microsoft Office is still the bedrock of business and now that the software giant's other products are catching on the stock is taking off, said Thomas Yorke, Managing Director at Oceanic Capital on Covestor. Yorke added that Microsoft has been very shareholder friendly with buybacks and dividends, and it has a massive pile of cash for M&A. Yorke is also bullish on shares of Blackstone, saying the private equity powerhouse trades at a cheap valuation considering its real estate holdings and dealmaking successes. Finally, Yorke said he remains bullish on the dollar as foreign central banks continue to weaken their currencies.
    Stock quotes in this video: MSFT, BX, UUP

    Sentiment: Strong Buy

  • sam_0534 by sam_0534 Jul 18, 2014 9:14 AM Flag

    COVERAGE REITERATED: Blackstone (BX) reiterated by RBC Capital Mkts. Reiterated rating Outperform.

  • Reply to

    stocastics very oversold..low risk buy here

    by sam_0534 Jul 18, 2014 2:06 PM
    sam_0534 sam_0534 Jul 18, 2014 11:11 PM Flag

    wellstocastics is just one tool...and yes a stock can stay oversold and continue down... there are a lot of scenerios.. one is the gap back last year in November can be filled..and the drop here has formed a flag with potential to continue to fall to fill the gap//that is the scarry option...nothing is low risk really with this type of stock.. I am generally not a risk taken. but for whatever reason I think the potential is very good..an announcement as ou know will make the stock fly..hoping it is up.. I have 6,000 shares now.. did not sell on the big spike last year..But my BIGGEST holding is 3,000 shares of BX and this is giving me room to speculate... IMHO

    Sentiment: Buy

  • or traders are just playing around???

  • sam_0534 sam_0534 Jul 18, 2014 9:20 AM Flag

    have a link for BREAN?.... didnt see it posted on Yahoo

CXW
35.11+0.11(+0.31%)Sep 19 4:04 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
TC PipeLines, LP
NYSEFri, Sep 19, 2014 4:00 PM EDT